Inozyme Pharma
INZY
INZY was delisted on the 30th of June, 2025.
50 hedge funds and large institutions have $71.2M invested in Inozyme Pharma in 2022 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 13 increasing their positions, 17 reducing their positions, and 9 closing their positions.
0.33% more ownership
Funds ownership: 73.21% → 73.54% (+0.33%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2% less funds holding
Funds holding: 51 → 50 (-1)
11% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 9
24% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 17
40% less capital invested
Capital invested by funds: $118M → $71.2M (-$47M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
+$2.33M |
| 2 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$1.91M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$869K |
| 4 |
BlackRock
New York
|
+$244K |
| 5 |
Renaissance Technologies
New York
|
+$70K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$3.59M |
| 2 |
CCM
CAAS Capital Management
New York
|
-$771K |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$606K |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$247K |
| 5 |
Millennium Management
New York
|
-$136K |
INZY Hedge Fund Activity: Q1 2022 in Review
50 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Inozyme Pharma (INZY) for Q1 2022, worth a combined $71.2M — down 40% from $118M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of INZY and 8 opened new positions — a net loss of 1 holder — while 17 trimmed existing stakes and 13 added.
The largest buyer was Janus Henderson Group, adding an estimated $2.33M. The largest seller was OrbiMed, exiting entirely with an estimated $3.59M sold.
- 50 institutional investors held Inozyme Pharma (INZY) as of Q1 2022, down from 51 in Q4 2021.
- Funds reported $71.2M of Inozyme Pharma stock for Q1 2022, down 40% quarter-over-quarter.
- 8 funds opened new Inozyme Pharma positions in Q1 2022 and 9 closed out, a net change of -1 holder.
- The largest Inozyme Pharma buyer in Q1 2022 was Janus Henderson Group, an estimated $2.33M added.
- The largest Inozyme Pharma seller in Q1 2022 was OrbiMed, an estimated $3.59M sold.
Based on aggregated 13F filings for Q1 2022.